Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in SLE
NCT06677801Phase 4Active, not recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of telitacicept in systemic lupus erythematosus (SLE), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Oct 2024; status: active, not recruiting.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06677801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06677801.